13.3 High-Risk Neonatal Conditions and Emergency Management

13.3 High-Risk Neonatal Conditions and Emergency Management

High-risk neonates—encompassing preterm infants, infants of diabetic mothers, neonates experiencing intrapartum asphyxia, and those with hemolytic isoimmunization—require vigilant assessment and rapid emergency intervention. In the delivery suite and neonatal intensive care unit (NICU), nurses must master standardized clinical protocols to stabilize compromised newborns. The international standard of emergency neonatal care is defined by the Neonatal Resuscitation Program (NRP), whose systematic hierarchy prioritizes establishing effective alveolar ventilation as the primary driver of cardiac recovery.

---

The Neonatal Resuscitation Program (NRP) Algorithmic Hierarchy

Unlike adult resuscitation, which focuses primarily on primary cardiac arrests, over 90% of neonatal resuscitations stem from acute respiratory failure and impaired gas exchange. Consequently, reversing hypoxia and establishing positive-pressure pulmonary ventilation almost invariably restores normal cardiac rate and systemic perfusion.

NRP Golden Minute & Resuscitation Algorithm:
[Birth] ---> 3 Rapid Questions: Term? Tone? Breathing/Crying?
                 | (If NO to any)
                 v
[0-30 sec]  WARM, DRY, STIMULATE, POSITION SNIFFING, CLEAR AIRWAY (Mouth then Nose)
                 |
                 v
[At 30 sec] Check HR & Breathing ---> HR < 100 bpm or Apnea/Gasping?
                 | (If YES)
                 v
[30-60 sec] POSITIVE-PRESSURE VENTILATION (PPV) at 40-60 breaths/min
            * Term (≥35w): 21% O2 | Preterm (<35w): 21-30% O2
                 |
                 v
[Chest Not Moving / HR < 100] ---> Execute MR SOPA Corrective Steps
                 |
                 v
[HR < 60 bpm despite 30 sec effective PPV] ---> 3:1 CHEST COMPRESSIONS with 100% O2
                 |
                 v
[HR remains < 60 bpm] ---> IV EPINEPHRINE (0.01 - 0.03 mg/kg via UVC)

The Initial 30 Seconds: The Golden Minute Foundation

Immediately following birth, the resuscitation team assesses three vital questions:

1. Is the infant born at term gestation?
2. Does the infant possess good muscle tone (flexion)?
3. Is the infant breathing or crying?

If the answer to all three questions is YES, the infant remains with the mother for immediate skin-to-skin contact, routine warming, and gentle airway clearance. If the answer to ANY question is NO, the neonate is immediately brought to a pre-heated radiant warmer to execute the initial stabilization steps within 30 seconds:

• Warm: Place under the radiant warmer.
• Position: Place the head in the "sniffing" position (neck slightly extended). Avoid hyperextension or excessive flexion, both of which collapse the narrow neonatal airway.
• Clear Airway: Suction secretions gently using a bulb syringe or suction catheter. Always suction the mouth first, then the nose ("M before N"). Suctioning the nose first stimulates reflex gasping, causing aspiration of pharyngeal secretions and amniotic fluid.
• Dry & Stimulate: Thoroughly dry the body and replace wet towels. Provide brief tactile stimulation by gently rubbing the back or flicking the soles of the feet.

Positive-Pressure Ventilation (PPV)

At 30 seconds of life, evaluate respirations and heart rate (auscultating the apical pulse for 6 seconds and multiplying by 10, or using 3-lead ECG monitoring):

• Indications for PPV: Apnea, gasping respirations, or a heart rate < 100 beats per minute.
• Rate: Deliver ventilations at 40 to 60 breaths per minute using the rhythmic cadence: "Breathe, two, three; Breathe, two, three; Breathe..."
• Initial Pressure: Peak Inspiratory Pressure (PIP) of 20 to 25 cmH2O.
• Oxygen Concentrations: For infants born at >= 35 weeks gestation, initiate PPV with 21% oxygen (room air). For preterm infants born < 35 weeks, initiate PPV with 21% to 30% oxygen. Titrate FiO2 based on pre-ductal pulse oximetry (probe attached to the right wrist or palm) targeting standard post-birth SpO2 ranges (60–65% at 1 min, 80–85% at 5 min, 85–95% at 10 min). Avoid initiating 100% O2 in term infants, which causes fatal oxidative free-radical reperfusion injury, retinal damage, and cerebral vasoconstriction.

Ventilation Corrective Steps: The MR SOPA Mnemonic

If the heart rate remains < 100 bpm or the chest is not visibly rising with PPV, the nurse must systematically troubleshoot ventilation using MR SOPA:

Chest Compressions Protocol

• Indication: Initiated ONLY when the heart rate remains < 60 beats per minute despite at least 30 seconds of effective PPV that produces bilateral chest expansion (preferably administered via an endotracheal tube).
• Compression-to-Ventilation Ratio: 3:1 ratio (3 compressions followed by 1 ventilation pause). Deliver 90 compressions and 30 breaths per minute (totaling exactly 120 events per minute). Each cycle lasts 2 seconds: "One-and-two-and-three-and-breathe; One-and-two-and-three-and-breathe..."
• Technique: The two-thumb encircling-hands technique is universally preferred over the two-finger technique because it generates superior coronary perfusion pressure, deeper systolic excursions, and less rescuer fatigue. Place both thumbs over the lower third of the sternum (just below the imaginary intermammary line), depressing the sternum to approximately one-third of the anterior-posterior (AP) diameter of the chest, allowing complete elastic chest recoil between compressions.
• Oxygen Titration: Simultaneously increase supplemental oxygen to 100% FiO2 when compressions are initiated.
• Reassessment: Reassess heart rate using ECG or auscultation after 60 seconds of coordinated compressions and ventilation.

Emergency Pharmacotherapy: Epinephrine & Volume Expansion

• Epinephrine: Indicated if the heart rate remains < 60 bpm despite 60 seconds of coordinated chest compressions with 100% O2 and effective ventilation via ETT.
  • Concentration: 1:10,000 (0.1 mg/mL).
  • Intravenous (IV) / Intraosseous (IO) Route: The preferred route via an Umbilical Venous Catheter (UVC). Dose: 0.01 to 0.03 mg/kg (equivalent to 0.1 to 0.3 mL/kg of 1:10,000 solution), followed immediately by a 3 mL normal saline flush.
  • Endotracheal (ET) Route: Utilized only temporarily while umbilical vascular access is being secured. Dose: 0.05 to 0.1 mg/kg (0.5 to 1.0 mL/kg of 1:10,000 solution), followed by several positive-pressure breaths.
• Volume Expander: Administer Normal Saline (0.9% NaCl) or O-negative packed red blood cells at 10 mL/kg IV over 5 to 10 minutes for acute hypovolemic shock (manifested as persistent pallor, delayed capillary refill > 3 seconds, weak thready pulses, or known maternal placental abruption/fetal hemorrhage unresponsive to resuscitation).

---

Neonatal Respiratory Distress Syndrome (RDS)

Etiology & Pathophysiology

Neonatal Respiratory Distress Syndrome (RDS), historically designated hyaline membrane disease, is the premier cause of respiratory failure in preterm infants born prior to 34 to 37 weeks gestation. RDS results from developmental deficiency in pulmonary surfactant, a phospholipid-protein complex (predominantly dipalmitoylphosphatidylcholine) synthesized by specialized type II alveolar pneumocytes beginning at 24 to 28 weeks and reaching physiological maturity by 35 weeks.

Surfactant dramatically reduces alveolar surface tension at the air-liquid interface, preventing alveolar collapse during expiration. In surfactant deficiency:

1. Surface tension surges, precipitating widespread end-expiratory microatelectasis.
2. Diffuse alveolar collapse creates profound ventilation-perfusion (V/Q) mismatch, progressive hypoxemia, hypercapnia, and combined respiratory and metabolic acidosis.
3. Acidosis and hypoxia trigger intense pulmonary arteriolar vasoconstriction, increasing right-to-left shunting across the ductus arteriosus and foramen ovale.
4. Damaged alveolar endothelial and epithelial membranes leak protein-rich fibrin exudates into alveolar lumens, forming dense, cellular hyaline membranes that severely impede gas diffusion.

Clinical Manifestations of Respiratory Distress

Signs typically manifest immediately at birth or progress rapidly within 4 to 6 hours:

• Tachypnea: Respiratory rate > 60 breaths/min (compensatory mechanism to maintain minute ventilation).
• Expiratory Grunting: A characteristic low-pitched sound produced as the neonate exhales against a partially closed vocal glottis; an innate physiological effort to create Positive End-Expiratory Pressure (PEEP) to prevent terminal alveolar collapse.
• Sternal, Intercostal, and Subcostal Retractions: Inward collapsing of the highly compliant, cartilaginous neonatal chest wall during negative-pressure inspiration.
• Nasal Flaring: Intermittent dilation of the nares on inspiration to reduce upper airway resistance.
• Central Cyanosis: Dusky or bluish discoloration of the tongue, oral mucous membranes, and trunk on room air.
• Chest Radiograph (CXR): Classic diffuse reticulogranular "ground-glass" appearance with prominent air bronchograms and low lung volumes.

Clinical Management & Surfactant Administration Protocol

• Antenatal Prevention: Maternal intramuscular administration of corticosteroids (Betamethasone 12 mg IM every 24 hours x 2 doses, or Dexamethasone 6 mg IM every 12 hours x 4 doses) to women presenting with threatened preterm delivery between 24 and 34 weeks gestation. Corticosteroids cross the placenta to accelerate fetal type II pneumocyte maturation and surfactant production.
• Continuous Positive Airway Pressure (CPAP): Early application of nasal CPAP (5 to 7 cmH2O) preserves functional residual capacity and prevents alveolar collapse.
• Exogenous Surfactant Replacement Therapy: Formulations derived from bovine or porcine lung extracts (e.g., Poractant alfa [Curosurf], Beractant [Survanta]). Administered directly into the tracheobronchial tree via an endotracheal tube.
  • Nursing Protocols for Surfactant Instillation:
    1. Warm the suspension vial to room temperature naturally; do not shake the vial (prevents protein denaturation and foaming).
    2. Thoroughly suction the neonate's endotracheal tube PRIOR to surfactant instillation to clear obstructing secretions.
    3. Instill surfactant into the trachea via a catheter passed through the ETT in divided aliquots, briefly rotating the infant's position to promote uniform anatomical distribution.
    4. DO NOT SUCTION THE ENDOTRACHEAL TUBE FOR AT LEAST 1 TO 2 HOURS FOLLOWING SURFACTANT INSTILLATION (unless life-threatening airway obstruction occurs) to allow full alveolar distribution and absorption.
    5. Closely monitor for rapid, dramatic increases in pulmonary compliance: ventilator PIP and oxygen concentrations must be titrated downward immediately to avoid barotrauma, pneumothorax, and hyperoxia.

---

Hyperbilirubinemia & Neonatal Jaundice

Jaundice (icterus) results from the tissue deposition of unconjugated (indirect) bilirubin, a fat-soluble breakdown pigment of heme catabolism. Neonates are physiologically predisposed to hyperbilirubinemia due to high circulating erythrocyte mass (hematocrit 55–65%), shortened RBC lifespan (70–90 days compared to 120 days in adults), deficient hepatic uridine diphosphate glucuronosyltransferase (UGT) enzyme activity, and increased enterohepatic reabsorption.

Jaundice Differential Diagnostic Matrix:
PHYSIOLOGIC JAUNDICE:    Appears AFTER 24 Hours (Days 2-4)  ---> Benign Adaptation
PATHOLOGIC JAUNDICE:     Appears WITHIN 24 Hours of Birth   ---> Hemolysis / Emergency
BREASTFEEDING JAUNDICE:  Days 2-4 (Suboptimal Intake)       ---> Increase Feed Frequency
BREAST MILK JAUNDICE:    Days 4-7 to Weeks (Milk Factors)   ---> Continue Breastfeeding

Acute Bilirubin Encephalopathy (ABE) & Kernicterus

Unconjugated, indirect bilirubin is highly lipid-soluble and unbound to albumin. When serum levels exceed albumin binding capacity, free bilirubin penetrates the blood-brain barrier and deposits toxically within the basal ganglia, hippocampus, and cranial nerve nuclei:

• Acute Bilirubin Encephalopathy (Early Phase): Lethargy, hypotonia, poor sucking, high-pitched shrill cry.
• Intermediate / Advanced Phase: Hypertonia, retrocollis (severe backward arching of the neck), opisthotonos (severe backward arching of the spine), fever, high-pitched screeching cry, seizures, and coma.
• Kernicterus (Chronic, Irreversible Damage): Choreoathetoid cerebral palsy, sensorineural hearing loss, upward gaze paralysis, dental enamel dysplasia, and severe intellectual impairment.

Phototherapy Nursing Care Bundle

Phototherapy utilizes blue-green light (wavelength 460 to 490 nm) to convert toxic, fat-soluble unconjugated bilirubin into water-soluble structural isomers (lumirubin) via photoisomerization, which are excreted in bile and urine without requiring hepatic conjugation.

1. Ocular Protection: Place opaque protective eye patches/shields securely over the closed eyes to prevent photochemical retinal burns. Remove eye patches periodically during parental feedings and skin-to-skin contact to inspect eyes for discharge, assess bonding, and provide visual stimulation.
2. Skin Exposure: Undress the infant completely except for a small diaper to maximize body surface area exposure to the irradiance lights. Turn and reposition the neonate every 2 to 3 hours to ensure uniform dermal light exposure.
3. Hydration & Nutrition: Maintain frequent feedings (breastfeed or formula feed every 2 to 3 hours). Bilirubin is primarily cleared via the gastrointestinal tract; frequent feedings stimulate peristalsis, preventing the enterohepatic reabsorption of bilirubin. Do NOT supplement with plain water or dextrose water, which causes hyponatremia and does not stimulate stooling.
4. Thermal Monitoring: Measure axillary body temperature every 2 to 4 hours to prevent phototherapy-induced hyperthermia or chilling from exposure.
5. Skin Care: DO NOT APPLY OILS, LOTIONS, OR OINTMENTS to the infant's skin during phototherapy; these agents act as heat conductors, causing severe dermal burns and blistering.
6. Laboratory Blood Draws: TURN OFF PHOTOTHERAPY LIGHTS TEMPORARILY when collecting blood for total serum bilirubin levels. Leaving phototherapy lights active during blood sampling degrades bilirubin in the collection tube, yielding falsely low laboratory values.
7. Bronze Baby Syndrome: A benign grayish-brown dermal and urinary discoloration occurring exclusively in neonates undergoing phototherapy who have elevated conjugated (direct) hyperbilirubinemia or biliary tract obstruction.

---

Neonatal Hypoglycemia

Pathophysiology & Risk Profiles

In utero, maternal glucose crosses the placenta via facilitated diffusion, maintaining fetal glucose concentrations at approximately 70% to 80% of maternal circulating levels. At delivery, umbilical cord clamping abruptly severs the continuous maternal glucose supply. The neonate must rapidly establish autonomous glucose homeostasis via hepatic glycogenolysis and gluconeogenesis, stimulated by surges in glucagon and catecholamines.

Neonatal hypoglycemia is clinically defined as a plasma or whole blood glucose level < 40 to 45 mg/dL (2.2 to 2.5 mmol/L) during the first 48 hours of life. Target pre-prandial glucose levels should remain >= 45 mg/dL.

High-Risk Neonatal Cohorts for Hypoglycemia:
+--------------------------------------------------------------------------------+
| 1. Infant of Diabetic Mother (IDM) / LGA: Chronic fetal hyperinsulinism.       |
| 2. SGA / IUGR / Preterm: Depleted hepatic glycogen & brown fat reserves.       |
| 3. Cold Stress / Sepsis / Asphyxia: Accelerated anaerobic glucose consumption. |
+--------------------------------------------------------------------------------+

• Infants of Diabetic Mothers (IDM) & Large for Gestational Age (LGA): Chronic maternal hyperglycemia induces fetal pancreatic beta-cell hyperplasia and fetal hyperinsulinism. Following birth, maternal glucose abruptly halts, but the neonate's hyperplastic beta-cells continue unregulated insulin secretion, driving profound rebound hyperinsulinemic hypoglycemia within 1 to 2 hours of delivery.
• Small for Gestational Age (SGA) & Preterm Infants: Possess severely diminished hepatic glycogen reserves, deficient adipose tissue, and immature gluconeogenic enzyme pathways.
• Perinatal Hypoxia, Cold Stress, & Sepsis: Hypermetabolic stress exponentially accelerates anaerobic glycolysis, rapidly consuming glycogen stores.

Clinical Manifestations

Neonatal brain tissue relies almost exclusively on continuous glucose metabolism. Untreated hypoglycemia leads to permanent neuronal injury, microcephaly, and developmental delay:

• Neuromuscular: Jitteriness and fine tremors (the hallmark clinical sign; can be distinguished from seizures because jitteriness is easily suppressed by gentle passive flexion or holding of the affected limb, whereas epileptic convulsions cannot be stopped by holding), exaggerated Moro reflex, irritability, high-pitched cry.
• Autonomic / Systemic: Lethargy, hypotonia, weak suck, refusal to feed, hypothermia, tachypnea, cyanosis, apnea (respiratory pauses >= 20 seconds), seizures, and coma.

Step-by-Step Clinical Management Protocol

1. Screening High-Risk Infants: Perform bedside point-of-care heel-stick glucose testing within 30 to 60 minutes after birth, and prior to feedings for the first 12 to 24 hours. Correct Heel-Stick Technique: Warm the heel for 5 to 10 minutes to promote capillary vasodilation. Puncture exclusively on the medial or lateral plantar borders of the heel. NEVER puncture the central plantar curvature or posterior heel curvature to prevent deep microvascular trauma and catastrophic calcaneal osteomyelitis.
2. Asymptomatic Hypoglycemia (Glucose 25 to 40 mg/dL in the first 4 hours, or 35 to 45 mg/dL at 4–24 hours):
   • Feed the neonate immediately with breast milk or commercial formula.
   • Administer oral 40% dextrose gel (200 mg/kg or 0.5 mL/kg) massaged directly into the buccal mucosa along the inner cheek.
   • Recheck blood glucose 30 to 60 minutes following the feed.
3. Symptomatic Hypoglycemia OR Blood Glucose < 25 mg/dL (or failing oral feeding/gel):
   • This represents an acute metabolic emergency requiring immediate intravenous therapy.
   • Administer an immediate intravenous bolus of 10% Dextrose in Water (D10W) at 2 mL/kg (200 mg/kg) infused slowly over 5 to 10 minutes.
   • Immediately establish a continuous IV maintenance infusion of D10W at a Glucose Infusion Rate (GIR) of 6 to 8 mg/kg/minute.
   • Recheck blood glucose in 15 to 30 minutes; titrate the GIR in increments of 1 to 2 mg/kg/min to maintain plasma glucose >= 45 to 50 mg/dL.
   • Never discontinue high-concentration intravenous dextrose abruptly; wean gradually to avert rebound hyperinsulinemic hypoglycemia.